130
Participants
Start Date
October 9, 2023
Primary Completion Date
April 25, 2025
Study Completion Date
April 25, 2025
Deucravacitinib
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0043, Ciudad Autónoma Buenos Aires
Local Institution - 0042, Rosario
Local Institution - 0002, New York
Local Institution - 0008, New York
Local Institution - 0062, New York
Local Institution - 0001, Winston-Salem
Local Institution - 0066, Boardman
Local Institution - 0052, Indianapolis
Local Institution - 0010, Houston
Local Institution - 0004, Santa Monica
Local Institution - 0015, Fountain Valley
Local Institution - 0050, Phoenix
Local Institution - 0009, Los Angeles
Local Institution - 0057, Skokie
Local Institution - 0053, Plainfield
Local Institution - 0029, Rockville
Local Institution - 0012, Detroit
Local Institution - 0005, East Windsor
Local Institution - 0055, Mayfield Heights
Local Institution - 0056, Pittsburgh
Local Institution - 0007, Norfolk
Local Institution - 0033, Mill Creek
Local Institution - 0037, Ciudad Autónoma Buenos Aires
Local Institution - 0034, Ciudad Autonoma Buenos Aires
Local Institution - 0058, Newmarket
Local Institution - 0060, Toronto
Local Institution - 0065, Montreal
Local Institution - 0054, Montreal
Local Institution - 0059, Québec
Local Institution - 0061, Saint-Jérôme
Local Institution - 0064, Saskatoon
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY